Lyn H Jones

List of Publications by Year in Descending Order

103 papers	4,870 citations	34 h-index	68 g-index
126 ext. papers	5,715 ext. citations	8.6 avg, IF	6.21 L-index

#	Paper	IF	Citations
103	Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition. *ACS Medicinal Chemistry Letters*, **2021**, 12, 1861-1865	4.3	4
102	Labeling Preferences of Diazirines with Protein Biomolecules. *Journal of the American Chemical Society*, **2021**, 143, 6691-6700	16.4	32
101	LanCLs add glutathione to dehydroamino acids generated at phosphorylated sites in the proteome. *Cell*, **2021**, 184, 2680-2695.e26	56.2	6
100	Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validation. *Cell Reports*, **2021**, 35, 109224	10.6	11
99	Design of next-generation covalent inhibitors: Targeting residues beyond cysteine. *Annual Reports in Medicinal Chemistry*, **2021**, 56, 95-134	1.6	2
98	Target Validation Using PROTACs: Applying the Four Pillars Framework. *SLAS Discovery*, **2021**, 26, 474-483	3.4	7
97	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. *Journal of Medicinal Chemistry*, **2021**, 64, 326-342	8.3	10
96	Fragment-based covalent ligand discovery. *RSC Chemical Biology*, **2021**, 2, 354-367	3	18
95	Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality. *Trends in Pharmacological Sciences*, **2020**, 41, 305-317	13.2	22
94	Pharmacological Correction of Proteinopathies via Lysosomal Degradation. *Biochemistry*, **2020**, 59, 727-728	3.2	
93	Structure-based design and analysis of SuFEx chemical probes. *RSC Medicinal Chemistry*, **2020**, 11, 10-17	3.5	34
92	Expanding chemogenomic space using chemoproteomics. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 3451-3453	3.4	5
91	Quantifying drug-target engagement in live cells using sulfonyl fluoride chemical probes. *Methods in Enzymology*, **2019**, 622, 201-220	1.7	2
90	Precision Retargeting: A Selective Covalent Inhibitor Illuminates CDK7 Biology. *Cell Chemical Biology*, **2019**, 26, 779-780	8.2	3
89	Reactive Chemical Probes: Beyond the Kinase Cysteinome. *Angewandte Chemie - International Edition*, **2018**, 57, 9220-9223	16.4	24
88	Reaktive chemische Sonden: Jenseits des Kinase-Cysteinoms. *Angewandte Chemie*, **2018**, 130, 9362-9365	3.6	4
87	Small-Molecule Kinase Downregulators. *Cell Chemical Biology*, **2018**, 25, 30-35	8.2	45

86	Applications of chemogenomic library screening in drug discovery. *Nature Reviews Drug Discovery*, **2017**, 16, 285-296	64.1	101
85	Quantitative measurement of intracellular HDAC1/2 drug occupancy using a -cyclooctene largazole thiol probe. *MedChemComm*, **2017**, 8, 767-770	5	5
84	Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA). *Journal of Medicinal Chemistry*, **2017**, 60, 3094-3108	8.3	14
83	Clinical chemoproteomics-Opportunities and obstacles. *Science Translational Medicine*, **2017**, 9,	17.5	17
82	Competition-based, quantitative chemical proteomics in breast cancer cells identifies new target profiles for sulforaphane. *Chemical Communications*, **2017**, 53, 5182-5185	5.8	23
81	A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I. *Human Molecular Genetics*, **2017**, 26, 3056-3068	5.6	21
80	Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain. *Journal of Medicinal Chemistry*, **2017**, 60, 5349-5363	8.3	24
79	Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor. *ACS Chemical Biology*, **2017**, 12, 1183-1187	4.9	16
78	Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes. *Journal of the American Chemical Society*, **2017**, 139, 680-685	16.4	180
77	Highly potent and selective Na1.7 inhibitors for use as intravenous agents and chemical probes. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4805-4811	2.9	18
76	Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells. *ACS Chemical Biology*, **2017**, 12, 2970-2974	4.9	18
75	Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay. *PLoS ONE*, **2017**, 12, e0184843	3.7	63
74	Covalent Enzyme Inhibition through Fluorosulfate Modification of a Noncatalytic Serine Residue. *ACS Chemical Biology*, **2017**, 12, 2015-2020	4.9	61
73	In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels. *PLoS ONE*, **2017**, 12, e0185079	3.7	13
72	Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2767-81	5.1	28
71	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4003-6	2.9	3
70	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. *Scientific Reports*, **2016**, 6, 30859	4.9	23
69	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. *ACS Chemical Biology*, **2016**, 11, 3442-3451	4.9	85

68	Modern advances in heterocyclic chemistry in drug discovery. *Organic and Biomolecular Chemistry*, **2016**, 14, 6611-37	3.9	349
67	Understanding the chemically-reactive proteome. *Molecular BioSystems*, **2016**, 12, 1728-30		6
66	Label-free technologies for target identification and validation. *MedChemComm*, **2016**, 7, 769-777	5	8
65	Design and development of histone deacetylase (HDAC) chemical probes for cell-based profiling. *Molecular BioSystems*, **2016**, 12, 1781-9		7
64	Cellular thermal shift and clickable chemical probe assays for the determination of drug-target engagement in live cells. *Organic and Biomolecular Chemistry*, **2016**, 14, 6179-83	3.9	19
63	Selectivity Determination of a Small Molecule Chemical Probe Using Protein Microarray and Affinity Capture Techniques. *ACS Combinatorial Science*, **2016**, 18, 611-615	3.9	5
62	Chemoselective Preparation of Clickable Aryl Sulfonyl Fluoride Monomers: A Toolbox of Highly Functionalized Intermediates for Chemical Biology Probe Synthesis. *ChemBioChem*, **2016**, 17, 1925-1930	3.8	28
61	TAK1 selective inhibition: state of the art and future opportunities. *Future Medicinal Chemistry*, **2015**, 7, 23-33	4.1	24
60	Sulfonyl fluorides as privileged warheads in chemical biology. *Chemical Science*, **2015**, 6, 2650-2659	9.4	253
59	Direct photocapture of bromodomains using tropolone chemical probes. *MedChemComm*, **2015**, 6, 1018-1023		8
58	A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS. *Molecular BioSystems*, **2015**, 11, 2709-12		8
57	Cell permeable affinity- and activity-based probes. *Future Medicinal Chemistry*, **2015**, 7, 2131-41	4.1	18
56	Click chemistry patents and their impact on drug discovery and chemical biology. *Pharmaceutical Patent Analyst*, **2015**, 4, 109-19	0.6	6
55	Recent advances in the molecular design of synthetic vaccines. *Nature Chemistry*, **2015**, 7, 952-60	17.6	81
54	Molecular hybridization yields triazole bronchodilators for the treatment of COPD. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5121-6	2.9	7
53	Thermodynamic Profiling of Carbonic Anhydrase Inhibitors. *Methods and Principles in Medicinal Chemistry*, **2015**, 137-154	0.4	
52	Know your target, know your molecule. *Nature Chemical Biology*, **2015**, 11, 368-72	11.7	74
51	Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. *Chemistry and Biology*, **2015**, 22, 1588-96		38

50	Rational targeting of active-site tyrosine residues using sulfonyl fluoride probes. *ACS Chemical Biology*, **2015**, 10, 1094-8	4.9	113
49	Target validation using in-cell small molecule clickable imaging probes. *MedChemComm*, **2014**, 5, 247-254	3	22
48	Understanding and applying tyrosine biochemical diversity. *Molecular BioSystems*, **2014**, 10, 952-69		46
47	Aryloxymaleimides for cysteine modification, disulfide bridging and the dual functionalization of disulfide bonds. *Chemical Communications*, **2014**, 50, 7139-42	5.8	37
46	Rare diseases. Foreword. *Future Medicinal Chemistry*, **2014**, 6, 969-70	4.1	
45	Synthetic phosphorylation of p38 recapitulates protein kinase activity. *Journal of the American Chemical Society*, **2014**, 136, 1698-701	16.4	40
44	TAK1 inhibition in the DFG-out conformation. *Chemical Biology and Drug Design*, **2013**, 82, 500-5	2.9	14
43	Target validation using chemical probes. *Nature Chemical Biology*, **2013**, 9, 195-9	11.7	297
42	A mild synthesis of N-functionalised bromomaleimides, thiomaleimides and bromopyridazinediones. *Tetrahedron Letters*, **2013**, 54, 3493-3495	2	36
41	Chemical motifs that redox cycle and their associated toxicity. *MedChemComm*, **2013**, 4, 1175	5	14
40	Developing irreversible inhibitors of the protein kinase cysteinome. *Chemistry and Biology*, **2013**, 20, 146-59		465
39	Medicinal chemistry of glucagon-like peptide receptor agonists. *Progress in Medicinal Chemistry*, **2013**, 52, 45-96	7.3	9
38	Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. *PLoS ONE*, **2013**, 8, e76557	3.7	65
37	Biotherapeutics. *RSC Drug Discovery Series*, **2013**,	0.6	4
36	Click-enabled heterotrifunctional template for sequential bioconjugations. *Organic and Biomolecular Chemistry*, **2012**, 10, 548-54	3.9	53
35	Chemistry and biology of biomolecule nitration. *Chemistry and Biology*, **2012**, 19, 1086-92		29
34	Welcome to Pharmaceutical Patent Analyst. Foreword. *Pharmaceutical Patent Analyst*, **2012**, 1, 1-2	0.6	2
33	Quantitative affinity-based chemical proteomics of TrkA inhibitors. *MedChemComm*, **2012**, 3, 322-325	5	2

32	Mehrfache orthogonale Konjugationen mit Molekülgerüsten: Anwendung in der chemischen Biologie und Wirkstoff-Forschung. *Angewandte Chemie*, **2012**, 124, 6426-6432	3.6	19
31	Molecular scaffolds using multiple orthogonal conjugations: applications in chemical biology and drug discovery. *Angewandte Chemie - International Edition*, **2012**, 51, 6320-6	16.4	90
30	Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease. *Future Medicinal Chemistry*, **2011**, 3, 1585-605	4.1	31
29	Squaramides: physical properties, synthesis and applications. *Chemical Society Reviews*, **2011**, 40, 2330-46	38.5	392
28	Inhalation by design. *Future Medicinal Chemistry*, **2011**, 3, 1563-5	4.1	3
27	Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-β2 agonist for the treatment of chronic obstructive pulmonary disease. *Journal of Medicinal Chemistry*, **2011**, 54, 6998-7002	8.3	14
26	Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers. *Chemical Biology and Drug Design*, **2011**, 77, 393-7	2.9	19
25	In-cell click labelling of small molecules to determine subcellular localisation. *Journal of Chemical Biology*, **2011**, 4, 49-53		16
24	Optimized glucuronidation of dual pharmacology β2 agonists/M3 antagonists for the treatment of COPD. *MedChemComm*, **2011**, 2, 870	5	7
23	Inhalation by design: dual pharmacology β2 agonists/M3 antagonists for the treatment of COPD. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2759-63	2.9	17
22	Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. *Molecular Therapy*, **2011**, 19, 2163-8	11.7	73
21	Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. *Journal of Virology*, **2011**, 85, 6353-68	6.6	98
20	Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry. *MedChemComm*, **2010**, 1, 309-318	5	61
19	Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors. *ChemMedChem*, **2009**, 4, 1985-9	3.7	58
18	Pyrazole NNRTIs 3: optimisation of physicochemical properties. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5603-6	2.9	20
17	Physicochemical drug properties associated with in vivo toxicological outcomes: a review. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 921-31	5.5	118
16	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. *Journal of Medicinal Chemistry*, **2009**, 52, 1219-23	8.3	45
15	Relaying stereochemistry through aromatic ureas: 1,9 and 1,15 remote stereocontrol. *Chemical Communications*, **2009**, 547-9	5.8	29

14	Helix persistence and breakdown in oligoureas of metaphenylenediamine: apparent diastereotopicity as a spectroscopic marker of helix length in solution. *Journal of the American Chemical Society*, **2008**, 130, 15193-202	16.4	74
13	Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors. *ChemMedChem* , **2008**, 3, 1756-62	3.7	13
12	Design and synthesis of a fluorescent muscarinic antagonist. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 825-7	2.9	14
11	Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 142-59	3.4	15
10	Synthetic chemistry-led creation of a difluorinated biaryl ether non-nucleoside reverse transcriptase inhibitor. *Organic and Biomolecular Chemistry*, **2007**, 5, 3431-3	3.9	7
9	A concise and selective synthesis of novel 5-aryloxyimidazole NNRTIs. *Organic Letters*, **2006**, 8, 1725-7	6.2	16
8	Oxaziridine-mediated amination of primary amines: scope and application to a one-pot pyrazole synthesis. *Organic Letters*, **2005**, 7, 713-6	6.2	72
7	Active immunization with a glycolipid transition state analogue protects against endotoxic shock. *Angewandte Chemie - International Edition*, **2002**, 41, 4241-4	16.4	6
6	Antibody catalysis of the oxidation of water. *Science*, **2001**, 293, 1806-11	33.3	226
5	Conversion of enediynes into quinones by antibody catalysis and in aqueous buffers: implications for an alternative enediyne therapeutic mechanism. *Journal of the American Chemical Society*, **2001**, 123, 3607-8	16.4	17
4	Total synthesis of (+)-zaragozic acid C. *Journal of Organic Chemistry*, **2000**, 65, 7020-32	4.2	46
3	Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 459-62	2.9	10
2	Total synthesis of (+)-zaragozic acid C. *Tetrahedron Letters*, **1998**, 39, 3337-3340	2	30
1	Medicinal Chemical Biology1-37		